Quanterix to Present at Multiple Upcoming Healthcare Conferences
- 45
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Kevin Hrusovsky, Chief Executive Officer, President and Chairman of Quanterix, will be presenting and hosting one-on-one meetings with investors at multiple high-profile healthcare conferences.
Hrusovsky will present at the eighth Annual Leerink Partners Global Healthcare Conference on Friday, March 1, 2019 at 9:30 a.m., EST, at the Lotte New York Palace in New York City, NY. He will also present at the 39th Annual Cowen and Company Health Care Conference, on Wednesday, March 13, 2019, at 10:40 a.m., EST, at the Marriott Copley in Boston, Mass. This presentation will be followed by a Q&A session at 11:20 a.m., EST.
To access the live webcast of Quanterix’ presentations, please visit the News & Events page within the Investors section of the Quanterix website at www.quanterix.com. Replays of the webcasts will be available on the Quanterix website for 90 days following the conference.
About Quanterix
Quanterix is a company that’s digitizing
biomarker analysis with the goal of advancing the science of precision
health. The company’s digital health solution, Simoa, has the potential
to change the way in which healthcare is provided today by giving
researchers the ability to closely examine the continuum from health to
disease. Quanterix’ technology is designed to enable much earlier
disease detection, better prognoses and enhanced treatment methods to
improve the quality of life and longevity of the population for
generations to come. The technology is currently being used for research
applications in several therapeutic areas, including oncology,
neurology, cardiology, inflammation and infectious disease. The company
was established in 2007 and is located in Lexington, Massachusetts. For
additional information, please visit https://www.quanterix.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190221005846/en/
- KBC Groupe: Mise à jour concernant le programme de rachat d’actions propres de KBC Groupe
- Changement au sein de la direction de Valora Food Service: Sebastian Kayser et Sebastian Gooding succèdent à Thomas Eisele
- Theranexus, Diverchim et l'INSERM bénéficient d'un financement de 4.7 millions d'euros dans le cadre de l'appel à projets " Innovations en Biothérapies et Bioproduction " de France 2030, pour développer un nouvel oligonucléotide antisens
- Communiqué de presse : L’étude de phase III LUNA 3 du rilzabrutinib pour le traitement de la thrombocytopénie immune a atteint son critère d’évaluation primaire
- Renault Group : Chiffre d’affaires Groupe du 1er trimestre 2024 à 11,7 milliards d’euros, +5,9 % à taux de change constants ; dans les starting-blocks pour l'offensive produits à venir
- Des circonstances exceptionnelles amplifient les résultats 2023